Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Acumen Pharmaceuticals Inc (ABOS)

Acumen Pharmaceuticals Inc (ABOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference GlobeNewswire - Tue Dec 2, 7:00AM CST

NEWTON, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc.  (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid...

ABOS : 1.9000 (-4.04%)
Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference GlobeNewswire - Tue Nov 18, 7:00AM CST

NEWTON, Mass., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta...

ABOS : 1.9000 (-4.04%)
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease GlobeNewswire - Mon Nov 17, 7:00AM CST

NEWTON, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta...

ABOS : 1.9000 (-4.04%)
Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights GlobeNewswire - Wed Nov 12, 6:00AM CST

Expect decision regarding the advancement of an Aβ oligomer-targeted Enhanced Brain Delivery TM product candidate in early 2026 Expect to report topline results for ALTITUDE-AD, a Phase 2 study to...

ABOS : 1.9000 (-4.04%)
Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors GlobeNewswire - Mon Nov 10, 7:00AM CST

NEWTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics...

ABOS : 1.9000 (-4.04%)
Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025 GlobeNewswire - Wed Nov 5, 3:00PM CST

NEWTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic...

ABOS : 1.9000 (-4.04%)
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference GlobeNewswire - Tue Nov 4, 3:00PM CST

NEWTON, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid...

ABOS : 1.9000 (-4.04%)
Doctor holding money by IherPhoto via iStock
2 ‘Strong Buy’ Stocks That Wall Street Believes Can Soar 360% to 780% Barchart - Tue Sep 23, 6:30AM CDT

These two growth stocks are attractive for investors seeking big upside in exchange for higher risk.

ELDN : 1.6100 (+1.26%)
$SPX : 6,872.99 (+0.23%)
ABOS : 1.9000 (-4.04%)
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire - Tue Aug 26, 3:00PM CDT

NEWTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid...

ABOS : 1.9000 (-4.04%)
Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights GlobeNewswire - Tue Aug 12, 6:00AM CDT

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Expect decision to advance an oligomer-targeted...

ABOS : 1.9000 (-4.04%)

Barchart Exclusives

SoFi Stock Breaks Below Key Moving Averages on $1.5B Offering. Should You Buy the Dip? Barchart - 11 minutes ago
SoFi shares sink as the management announces a $1.5 billion convertible notes offering. Here’s the case against initiating a new position in SOFI stock at current levels. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot